Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study.
Authors
Antoni, Gunnar
Al Azzam, Wasfi
Bergström, Mats
Biswas, Swethajit
Chen, Chao
Cleveland, Matthew
Cookson, Louise
Galette, Paul
Janiczek, Robert L
Kwong, Raymond Y
Lukas, Mary Ann
Millns, Helen
Richards, Duncan
Schneider, Ian
Solomon, Scott D
Sörensen, Jens
Storey, James
Thompson, Douglas
van Dongen, Guus
Vugts, Danielle J
Wall, Anders
Wikström, Gerhard
Falk, Rodney H
Publication Date
2022-02-13Journal Title
BMC Cardiovasc Disord
ISSN
1471-2261
Publisher
Springer Science and Business Media LLC
Volume
22
Issue
1
Language
en
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Wechalekar, A., Antoni, G., Al Azzam, W., Bergström, M., Biswas, S., Chen, C., Cheriyan, J., et al. (2022). Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study.. BMC Cardiovasc Disord, 22 (1) https://doi.org/10.1186/s12872-021-02407-6
Abstract
BACKGROUND: In a Phase I study treatment with the serum amyloid P component (SAP) depleter miridesap followed by monoclonal antibody to SAP (dezamizumab) showed removal of amyloid from liver, spleen and kidney in patients with systemic amyloidosis. We report results from a Phase 2 study and concurrent immuno-positron emission tomography (PET) study assessing efficacy, pharmacodynamics, pharmacokinetics, safety and cardiac uptake (of dezamizumab) following the same intervention in patients with cardiac amyloidosis. METHODS: Both were uncontrolled open-label studies. After SAP depletion with miridesap, patients received ≤ 6 monthly doses of dezamizumab in the Phase 2 trial (n = 7), ≤ 2 doses of non-radiolabelled dezamizumab plus [89Zr]Zr-dezamizumab (total mass dose of 80 mg at session 1 and 500 mg at session 2) in the immuno-PET study (n = 2). Primary endpoints of the Phase 2 study were changed from baseline to follow-up (at 8 weeks) in left ventricular mass (LVM) by cardiac magnetic resonance imaging and safety. Primary endpoint of the immuno-PET study was [89Zr]Zr-dezamizumab cardiac uptake assessed via PET. RESULTS: Dezamizumab produced no appreciable or consistent reduction in LVM nor improvement in cardiac function in the Phase 2 study. In the immuno-PET study, measurable cardiac uptake of [89Zr]Zr-dezamizumab, although seen in both patients, was moderate to low. Uptake was notably lower in the patient with higher LVM. Treatment-associated rash with cutaneous small-vessel vasculitis was observed in both studies. Abdominal large-vessel vasculitis after initial dezamizumab dosing (300 mg) occurred in the first patient with immunoglobulin light chain amyloidosis enrolled in the Phase 2 study. Symptom resolution was nearly complete within 24 h of intravenous methylprednisolone and dezamizumab discontinuation; abdominal computed tomography imaging showed vasculitis resolution by 8 weeks. CONCLUSIONS: Unlike previous observations of visceral amyloid reduction, there was no appreciable evidence of amyloid removal in patients with cardiac amyloidosis in this Phase 2 trial, potentially related to limited cardiac uptake of dezamizumab as demonstrated in the immuno-PET study. The benefit-risk assessment for dezamizumab in cardiac amyloidosis was considered unfavourable after the incidence of large-vessel vasculitis and development for this indication was terminated. Trial registration NCT03044353 (2 February 2017) and NCT03417830 (25 January 2018).
Keywords
Research Article, Structural Diseases, Heart Failure & Congenital, Cardiac amyloidosis, Miridesap, Dezamizumab, Positron emission tomography, Immuno-PET, Serum amyloid P component, Systemic amyloidosis
Sponsorship
gsk (NCT03044353, NCT03417830)
Identifiers
s12872-021-02407-6, 2407
External DOI: https://doi.org/10.1186/s12872-021-02407-6
This record's URL: https://www.repository.cam.ac.uk/handle/1810/334009
Rights
Licence:
http://creativecommons.org/licenses/by/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk